You searched for COVID-19 Research - Page 4 of 4

Office of Health Economics

OHE

Leading intellectual authority on global health economics

Search publications, topics, authors and more

Newsletter SignupSubscribe

News & Insights

News
Events
Insights
Bulletin

News
Events
Insights
Bulletin

News & Insights

News
Events
Insights
Bulletin

Newsletter SignupSubscribe

News
Events
Insights
Bulletin

Search publications, topics, authors and more

OHE

Research & Publications
News & Insights
Education
Innovation Policy Prize

Events
About Us
OHE Experts
Contact Us

Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:

Antimicrobial Resistance (AMR)
Biosimilars
Cell and Gene Therapies
Chronic Diseases
Combination Therapies
COVID-19 Research
Digital Health
Drug Development/R&D
Emerging Markets
EQ-5D and PROMs
Health Care Systems
Health Data and Statistics
Health Technology Assessment
Precision Medicine
Real-World Evidence
Use of Medicines
Value-Based Pricing
Vaccine Research

Economics of Innovation
Measuring and Valuing Outcomes
Policy, Organisation and Incentives in Health Systems
Value, Affordability and Decision Making

News & Insights

News
Events
Insights
Bulletin

Education

Education Hub
OHE Graduate School
EVIA Programme
IRA Programme

Innovation Policy Prize

The Prize Fund
2022 Prize Fund

Search publications, topics, authors and more

Latest Research & Publications

Combination Therapies
Value, Affordability, and…
Rare and Orphan Diseases

A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases

Economics of Innovation
Health Policy and Regulation

The Lower Drug Costs Now Act and Pharmaceutical Innovation

COVID-19 Research
Economics of Innovation
Determining Value

Working Towards a Sustainable, Healthy Market for Vaccines: a Comprehensive Framework to Support Policy Dialogue and Decision-Making

Health Technology Assessment…
Measuring and Valuing Outcomes

How is Quality of Life Measured for Health Technology Assessments?

Cell and Gene Therapies
Economics of Innovation
Market Access

Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies

Cell and Gene Therapies
Economics of Innovation
Health Policy and Regulation

Exploring the Financial Sustainability of Gene Therapies

COVID-19 Research
Value, Affordability, and…
Health Policy and Regulation

Key Factors on How to Procure, Pay, Distribute and Use Vaccines for COVID-19: A European Perspective

Cell and Gene Therapies
Economics of Innovation
Health Policy and Regulation

The Promise of Gene Therapies: Are We Ready?

All Publications

Filter by:

Antimicrobial Resistance (AMR)

Biosimilars

Cell and Gene Therapies

Chronic Diseases

Combination Therapies

COVID-19 Research

Digital Health

Drug Development/R&D

Emerging Markets

EQ-5D and PROMs

Health Care Systems

Health Data and Statistics

Health Technology Assessment

Precision Medicine

Real-World Evidence

Use of Medicines

Value-Based Pricing

Vaccine Research

Economics of Innovation

Measuring and Valuing Outcomes

Policy, Organisation and Incentives in Health Systems

Value, Affordability and Decision Making
News

Events

Insights

Bulletin
Education Hub

OHE Graduate School

EVIA Programme

IRA Programme
The Prize Fund

2022 Prize Fund

Events
About Us
OHE Experts
Contact Us

Newsletter SignupSubscribe

Filter results by

Theme

Select the product option you would like to filter Theme

Economics of Innovation Measuring and Valuing Outcomes Policy, Organisation and Incentives in Health Systems Value, Affordability, and Decision Making

Topic

Select the product option you would like to filter Topic

Antimicrobial Resistance (AMR) Biosimilars Cell and Gene Therapies Chronic Diseases Combination Therapies COVID-19 Research Digital Health Drug Development/R&D Educational Emerging Markets EQ-5D and PROMs Health Care Systems Health Data and Statistics Health Technology Assessment (HTA) Innovation Policy Prize OHE Consulting Precision Medicine Real World Evidence (RWE) Research Use of Medicines Vaccines Value-Based Pricing

Tag

Select the product option you would like to filter Tag

Cancer Cardiovascular Disorders Caring burden Clinical Outcomes Commentary Competition Dermatology Determining Value Economic Evaluation Egypt Epidemiology and Public Health Gene therapies Generics Health Policy and Regulation Healthcare Delivery Healthcare Expenditure Healthcare Funding India Infectious Diseases Inflation Reduction Act Injury and Trauma Innovation Israel Market Access Mental Health Pharmaceutical Industry Policy Analysis Pricing and Reimbursement Primary Care Quality of Care Quality of Life Rare and Orphan Diseases Research Funding Resource Allocation Saudi Arabia Slovak Republic Sustainability Value based pricing

Date 1

Select the product option you would like to filter Date

Date From

Month From

Year From

Date To

Month To

Year To

Author

Select the product option you would like to filter Author

Search authors

Julia Toth Anjeli Sharma Nathalie Largeron Rachel Allen Róbert Babeľa Stuart Carroll Nancy Devlin Alastair Fischer Lou Garrison Victoria Serra-Sastre

Content Type

Select the product option you would like to filter Content Type

news story insight events podcast bulletin publications

Doctor mask_AdobeStock_341598540_landscape

Bulletin
January 2023

January 2023

Insight
January 2023

Combination Therapies: A Step Forward to the Value Attribution Problem

Digital Health

Navigating the Landscape of Digital Health – United Kingdom

December-Bulletin_Adobe_-ValentinValkov-scaled-1

Bulletin
December 2022

December 2022

Insight
December 2022

G7 Investments in New Antibiotics Would Pay Off – For Everyone

jacek-dylag-IiQXLbTTQCw-unsplash-scaled-1

Insight
December 2022

ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

Insight
November 2022

The World Needs New Antibiotics. A Proposed US Program to Develop Them Offers a High Pay-Off

Bulletin
November 2022

November 2022

Sustainability

Supporting the Era of Green Pharmaceuticals in the UK

Insight
October 2022

The Economics of Antibiotics – Part 4: What Does the Antibiotics Market of the Future Look Like?

Insight
October 2022

The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics

Insight
October 2022

The Economics of Antibiotics – Part 2: Value Assessment within the NICE-NHS AMR Pilot

Insight
October 2022

The Economics of Antibiotics – Part 1: Why NICE and NHS England are Testing an Innovative HTA and Payment Model to Tackle Antimicrobial Resistance

In a bull voice. A yellow background with a woman’s hand in fr

Bulletin
October 2022

October 2022

Leading intellectual authority on global health economics

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Cookies Policy

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Twitter

Facebook

Copy

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Enable or Disable Cookies

Please enable Strictly Necessary Cookies first so that we can save your preferences!

A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases

The Lower Drug Costs Now Act and Pharmaceutical Innovation

Working Towards a Sustainable, Healthy Market for Vaccines: a Comprehensive Framework to Support Policy Dialogue and Decision-Making

How is Quality of Life Measured for Health Technology Assessments?

Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies

Exploring the Financial Sustainability of Gene Therapies

Key Factors on How to Procure, Pay, Distribute and Use Vaccines for COVID-19: A European Perspective

The Promise of Gene Therapies: Are We Ready?

All Publications

Filter results by

January 2023

Combination Therapies: A Step Forward to the Value Attribution Problem

Navigating the Landscape of Digital Health – United Kingdom

December 2022

G7 Investments in New Antibiotics Would Pay Off – For Everyone

ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”

2021 OHE Annual Report to the Charity Commission

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

The World Needs New Antibiotics. A Proposed US Program to Develop Them Offers a High Pay-Off

November 2022

Supporting the Era of Green Pharmaceuticals in the UK

The Economics of Antibiotics – Part 4: What Does the Antibiotics Market of the Future Look Like?

The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics

The Economics of Antibiotics – Part 2: Value Assessment within the NICE-NHS AMR Pilot

The Economics of Antibiotics – Part 1: Why NICE and NHS England are Testing an Innovative HTA and Payment Model to Tackle Antimicrobial Resistance

October 2022